- Home
- BTOG vs BGMS Comparison
BTOG vs BGMS Comparison
Compare BTOG & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BTOG | BGMS |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | Singapore | Malaysia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BTOG | BGMS |
|---|---|---|
| Price | $4.24 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.9K | 31.1K |
| Earning Date | 03-31-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $39,495.00 | ★ $81,000.00 |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.46 |
| 52 Week Low | $3.39 | $1.16 |
| 52 Week High | $60.60 | $100.75 |
Technical Indicators
Market Signals| Indicator | BTOG | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 77.40 | 37.63 |
| Support Level | $3.65 | $1.28 |
| Resistance Level | $5.96 | $1.36 |
| Average True Range (ATR) | 0.55 | 0.12 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 69.89 | 6.23 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.